CardioKinetix, a Menlo Park, Calif.-based medical device company, has completed the $23 million second-tranche of its Series E financing, bringing the total round to $48 million. Panorama Capital is the company’s newest investor. It joins previous investors U.S. Venture Partners, JPMorgan Partners, New Leaf Venture Partners, SV Life Sciences, H&Q Healthcare Investors, and H&Q Life Sciences Investors.

Medical device company CardioKinetix has apointed Maria Sainz as president and chief executive officer. Recently Sainz served as general manager of Stryker Neurovascular, which acquired Concentric Medical in October 2011 under her leadership as president and CEO. CardioKinetix is backed by SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners, Panorama Capital, and H&Q [...]

Veniti, a startup company focused on the treatment of venous disease, has added Scott Solano to its executive team as chief operating officer (COO). Solano joins Veniti with more than 22 years of experience designing, testing and producing medical devices. Veniti raised over $15 million in 2011, led by Baird Venture Partners and H&Q Healthcare [...]

CardioKinetix, a medical device company developing transcatheter implants, has raised $44 million in a two-tranche Series E financing. New investors SV Life Sciences and New Leaf Venture Partners led the round, which included return backers including U.S. Venture Partners, J.P. Morgan Partners, H&Q Healthcare Investors and H&Q Life Sciences Investors. The company’s device, dubbed Parachute, is implanted into the left ventricle of the heart in a simple catheter lab procedure and is intended to treat patients with heart failure resulting from a myocardial infarction or heart attack.

Veniti, a Saint Louis-based medical device company, has raised a $13.5 million Series A round led by Baird Venture Partners, H&Q Healthcare Investors, and H&Q Life Sciences Investors. Veniti develops devices for treating venous disease, including a stent system. Its first products are expected to be available later this year, according to the company. PRESS [...]